Avery Dennison unveils tamper-evident material range for pharma sector

‘Drug counterfeiting is a major global problem. Patient safety is compromised by product manipulation and substitution, and manufacturers can experience damage to their brand image, sales, and revenue,’ explained Gabriela Gregor, Avery Dennison’s project manager for pharmaceutical labeling. ‘Our products can change the game in protecting patient safety and safeguarding manufacturer reputation.’

One key product range in the portfolio is the Tamper-evident Seal Range, which, when combined with newly formulated adhesive S799P, makes tampering with cartons more difficult, and eases compliance with the EU Medicine Directive 2011/62/EU, which is designed to prevent ‘falsified medicines’ from entering the legal prescription supply chain, and also applies to some over-the-counter products.